The Importance of Mealtime Control
Glossary
Blood Sugar
The main sugar found in the blood and the body's main source of energy. Also called blood glucose.
The main sugar found in the blood and the body's main source of energy. Also called blood glucose.
Glossary
Blood Sugar Levels
The amount of sugar (glucose) in a given amount of blood. It is reported as the number of milligrams of glucose in a deciliter of blood, or mg/dL.
The amount of sugar (glucose) in a given amount of blood. It is reported as the number of milligrams of glucose in a deciliter of blood, or mg/dL.
Glossary
A1C (glycosylated hemoglobin)
A blood test that measures average blood sugar over the past 2 to 3 months.
A blood test that measures average blood sugar over the past 2 to 3 months.
- Before meals (also called your "fasting blood glucose")
- Two hours after meals (also called your "postprandial blood glucose")
- If you have an A1C between 7.3% and 9.3%, your overall control may be similarly impacted by your premeal and after-meal blood sugar levels.1 If you don't get your after-meal levels in control, you may not be able to hit your A1C target.
- High blood sugar after meals can make you feel worn out. Your thinking may not be as sharp as usual.
- High after-meal blood sugars may increase your risk for heart and blood vessel problems.2
Both Blood Sugar Levels Can Similarly Impact Control1
References:
1. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26(3):881-5.
2. The DECODE study group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 1999;354(9):617-621.
1. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26(3):881-5.
2. The DECODE study group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 1999;354(9):617-621.
Important Safety Information
Humalog, Humalog Mix75/25, and Humalog Mix50/50 are for use in patients with diabetes to control high blood sugar. Humalog should be used with a longer-acting insulin, except when used in combination with sulfonylureas in patients with type 2 diabetes.
Humalog insulins are contraindicated during episodes of hypoglycemia and in patients sensitive to Humalog or one of its excipients. The safety and effectiveness of Humalog in patients less than 3 years of age have not been established. Safety and effectiveness of Humalog Mix75/25 and Humalog Mix50/50 in patients less than 18 years of age have not been established. There are no clinical studies of the use of Humalog insulins in pregnancy or nursing mothers.
Potential side effects associated with the use of all insulins include low blood sugar, weight gain, low blood potassium, changes in fat tissue at the site of injection, and allergic reactions, both general and local. Humalog Mix75/25 and Humalog Mix50/50 should not be mixed with another insulin. Starting or changing insulin therapy should be done cautiously and only under medical supervision.
Humalog insulins are available by prescription only. See the Humalog, Humalog Mix75/25, and Humalog Mix50/50 Patient Product Information for important facts about these products.
Humalog is a registered trademark of Eli Lilly and Company. Humalog Mix75/25 and Humalog Mix50/50 are trademarks of Eli Lilly and Company.
Humalog, Humalog Mix75/25, and Humalog Mix50/50 are for use in patients with diabetes to control high blood sugar. Humalog should be used with a longer-acting insulin, except when used in combination with sulfonylureas in patients with type 2 diabetes.
Humalog insulins are contraindicated during episodes of hypoglycemia and in patients sensitive to Humalog or one of its excipients. The safety and effectiveness of Humalog in patients less than 3 years of age have not been established. Safety and effectiveness of Humalog Mix75/25 and Humalog Mix50/50 in patients less than 18 years of age have not been established. There are no clinical studies of the use of Humalog insulins in pregnancy or nursing mothers.
Potential side effects associated with the use of all insulins include low blood sugar, weight gain, low blood potassium, changes in fat tissue at the site of injection, and allergic reactions, both general and local. Humalog Mix75/25 and Humalog Mix50/50 should not be mixed with another insulin. Starting or changing insulin therapy should be done cautiously and only under medical supervision.
Humalog insulins are available by prescription only. See the Humalog, Humalog Mix75/25, and Humalog Mix50/50 Patient Product Information for important facts about these products.
Humalog is a registered trademark of Eli Lilly and Company. Humalog Mix75/25 and Humalog Mix50/50 are trademarks of Eli Lilly and Company.
